The latest price target for Regulus Therapeutics (NASDAQ:RGLS) was reported by Oppenheimer on August 14, 2024. The analyst firm set a price target for $7.00 expecting RGLS to rise to within 12 months (a possible 363.58% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Regulus Therapeutics (NASDAQ:RGLS) was provided by Oppenheimer, and Regulus Therapeutics reiterated their outperform rating.

There is no last upgrade for Regulus Therapeutics

There is no last downgrade for Regulus Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regulus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regulus Therapeutics was filed on August 14, 2024 so you should expect the next rating to be made available sometime around August 14, 2025.

While ratings are subjective and will change, the latest Regulus Therapeutics (RGLS) rating was a reiterated with a price target of $7.00 to $7.00. The current price Regulus Therapeutics (RGLS) is trading at is $1.51, which is out of the analyst’s predicted range.